Skip to main content

Information updates

FASENRA (benralizumab) approved for eosinophilic granulomatosis with polyangiitis (EGPA)

This news item was issued on 8 April 2025 by Jill Smith, CEO of ASCIA, the peak professional body for clinical immunology and allergy in Australia and New Zealand.  

ASCIA Members please log in to view.

Register to read more …